MMED

MindMed to Commence Groundbreaking LSD Microdosing Study Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body NEW YORK, Jan. 12, 2021 -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced an innovative randomi... Read More...

Bolsters Cash on Hand to CAD $183.0m (USD $144.4m)NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, Jan. 7, 2021 -- Mind Medicine (MindMed) Inc. (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ) ("MindMed") is pleased to announce that it has closed its previously announced bought deal short for... Read More...

The Top Companies Addressing Mental Health CrisisATLANTA, Jan. 04, 2021 -- 2020 was a banner year for investors in psychedelic companies as investors in Mind Medicine (MindMed) Inc. (OTCQB: MMEDF), 20/20 Global, Inc. (OTC: TWGL), Compass Pathways (NASDAQ: CMPS), and Numinus Wellness Inc. (OTC: LKYSF) saw their money triple and even quadru... Read More...

Project Lucy Submits Pre-IND Briefing Package to the FDA; Agrees Q1 Interim Analysis of Swiss Phase 2a Trial of LSD Assisted Therapy for Anxiety DisordersNEW YORK and BASEL, Switzerland, Nov. 16, 2020 -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, has received a positive response on its ... Read More...

Data to Support MindMed's Project Lucy in Preparing Phase 2b Trial for Anxiety DisordersNEW YORK, Nov. 2, 2020 -- MindMed (NEO: MMED, OTCQB: MMEDF), the leading psychedelic medicine biotech company in partnership with University Hospital Basel's Liechti Lab announces the completion and publication of a Phase 1 study on the acute dose depe... Read More...

Post-Financing Cash Reserves of CAD $50.1m (USD $37.8m) to Enable Continued Advancement of Diverse and Growing Clinical Trial Pipeline of PsychedelicsNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, Oct. 30, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF) ("MindMed" o... Read More...

FINANCING TO SUPPORT THE DEVELOPMENT OF MINDMED'S GROWING PIPELINE OF PSYCHEDELIC INSPIRED MEDICINES AND EXPERIENTIAL THERAPIESNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, Oct. 27, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) ("MindMed" or the "Company") is pl... Read More...

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./NEW YORK, Oct. 9, 2020 - Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) ("MindMed"), the leading neuro-pharmaceutical company for psychedelic inspired me... Read More...

MindMed Collaborating On Study Comparing Effects Induced By LSD and Psilocybin Under Exclusive License Agreement With University Hospital Basel Liechti Lab BASEL, Switzerland, Sept. 24, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading drug development company for psychedelic inspired medicines, announces that the ... Read More...

NEW YORK, Sept. 21, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is evaluating an expanded United States investor base through an up-listing on the NASDAQ Capital Market ("NASDAQ").Mindmed logo (PRNewsfoto/Mind Medicine, Inc. (Mindmed))As ... Read More...

MindMed is funding a Phase 1 Clinical Trial at University Hospital Basel Liechti LabNEW YORK, Aug. 25, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines and the University Hospital Basel's Liechti Lab are now combining MDMA and LSD in a groundbreaking... Read More...

Applauds Health Canada's Approval Of Psilocybin Compassionate Access For PatientsNEW YORK, Aug. 6, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has engaged renowned psychedelic assisted therapy expert Dr. Peter Gasser as an advisor to its LSD experiential therapy program Pr... Read More...

MindMed, in collaboration with the University Hospital Basel, has filed two separate patent applications for technologies to screen and optimize the dosing of MDMA and LSD BASEL, Switzerland, June 24, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines,... Read More...

MindMed Is Collaborating on a Phase 2 Clinical Trial of LSD For Cluster Headaches with University Hospital Basel's Liechti LabBASEL, Switzerland , June 8, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), is supporting and collaborating on a Phase 2 clinical trial evaluating LSD for the treatment of cluster headaches at Unive... Read More...

Adds Clinical Trial Site at University Hospital Basel and Appoints World Leading Psychedelics Researcher Dr. Matthias Liechti as Principal InvestigatorBASEL, Switzerland, June 2, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF) is expanding its Phase 2a clinical trial of LSD microdosing for Adult ADHD. MindMed is the leading ... Read More...

NEW YORK , May 27, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is now adding the psychedelic compound MDMA to its R&D pipeline.MindMed Adds MDMA to Develop Next-Gen Psychedelic TherapiesThe latest development comes as part of MindMed's excl... Read More...

Signs Clinical Trial Agreement With Maastricht University In Netherlands NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO , May 12, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED; OTC: MMEDF) ("MindMed" or the "Company") is pleased to announce that, on May 8, 2020 , it has entered ... Read More...

Advances Discovered in Collaboration with University Hospital Basel's Liechti Laboratory and Aims To Enhance Therapeutic Potential of PsychedelicsNEW YORK, April 21, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), in collaboration with University Hospital Basel's Liechti Laboratory, has discovered and filed a patent applica... Read More...

Company is actively developing and scaling manufacturing processes for 18-MC and LSD APIs to be used in the company's future drug trialsNEW YORK, April 20, 2020 -- Mind Medicine (MindMed), Inc. (NEO: MMED; OTCQB: MMEDF), the leading psychedelic pharmaceutical company, today announced the promotion of pharmaceutical industry veteran Jeanne... Read More...

NEW YORK, April 17, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED; OTCQB: MMEDF) (the "Company" or "MindMed"), the leading psychedelic pharmaceutical company, is pleased to announce that the Company has graduated from the OTC Pink Open Market to the OTCQB Venture Market ("OTCQB"). MindMed's subordinate voting shares will commence tradin... Read More...

NEW YORK, April 16, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. The safety trial has commenced on time and as scheduled, even during the COVID-19 pandemic. 18-MC is a proprietary, orall... Read More...